文献速递糖尿病肥胖与代谢综合征

可溶性鸟苷酸环化酶刺激剂普拉西呱在2型糖尿病合并高血压参与者中的探索性、随机、安慰剂对照14天试验

An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension.
PubMed 文献 · Diabetologia · 2019-12-19

这项IIA期双盲安慰剂对照试验在26例接受稳定降糖降压治疗的2型糖尿病合并高血压参与者中评估普拉西呱的安全性、耐受性、药代动力学和药效学。参与者按3:5:5随机分为安慰剂组(n=6)、普拉西呱40 mg每日一次组(n=10)和普拉西呱20 mg每日两次7天后40 mg每日一次组(n=10),治疗14天。普拉西呱总体耐受良好,除1例严重不良事件(上消化道出血)外,在代谢和血压指标上呈积极趋势,支持进一步临床研究。

要点

  • 普拉西呱治疗14天总体耐受良好,仅报告1例严重不良事件(上消化道出血)。
  • 与安慰剂相比,普拉西呱组空腹血糖、总胆固醇、LDL胆固醇和HOMA-IR的基线变化差异呈有利趋势。
  • 普拉西呱未影响血小板功能或反应性充血指数,血浆不对称二甲基精氨酸水平较安慰剂降低。

核心结论

  • 在接受标准治疗的2型糖尿病合并高血压参与者中,普拉西呱治疗14天耐受良好(除1例严重不良事件外),在代谢和血压变量上显示积极趋势,结果支持对普拉西呱进行进一步临床研究。

研究设计与样本

  • IIA期、双盲、安慰剂对照试验,纳入26例接受稳定降糖和降压治疗的2型糖尿病合并高血压参与者。
  • 参与者按3:5:5比例随机分为三组:安慰剂组(n=6)、普拉西呱40 mg每日一次第1-14天组(n=10)、普拉西呱20 mg每日两次第1-7天随后40 mg每日一次第8-14天组(n=10)。
  • 评估包括治疗中出现的不良事件、药代动力学、代谢变量、24小时血压和心率、血小板功能、反应性充血指数(RHI)和血浆生物标志物。
  • 参与者、申办方、研究者和临床研究工作人员(指定药房人员除外)对分组设盲。

主要发现

  • 接受普拉西呱治疗14天的参与者与安慰剂相比,空腹血糖的基线变化最小二乘均值差异为-0.7(95%CI -1.8, 0.4)mmol/l。
  • 总胆固醇的基线变化差异为-0.7(95%CI -1.1, -0.2)mmol/l,LDL胆固醇为-0.5(95%CI -1.0, -0.1)mmol/l。
  • 未接受胰岛素治疗者中HOMA-IR的基线变化差异为-23(95%CI -56, 9)。
  • 平均24小时平均动脉压和心率的基线变化差异分别为-5(95%CI -10, 1)mmHg和3(95%CI -1, 6)次/分。
  • 除1例严重不良事件(上消化道出血)外,普拉西呱耐受良好;普拉西呱未影响血小板功能或RHI;探索性生物标志物中,普拉西呱组血浆不对称二甲基精氨酸水平较安慰剂组降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Praliciguat (IW-1973), a soluble guanylate cyclase stimulator, amplifies nitric oxide signalling. This exploratory trial investigated the safety, tolerability, pharmacokinetic profile and pharmacodynamic effects of praliciguat in individuals with type 2 diabetes and hypertension. METHODS: This Phase IIA, double-blind, placebo-controlled trial investigated praliciguat in 26 participants with type 2 diabetes and hypertension on stable glucose- and BP-lowering therapies. Participants were randomly allocated in a 3:5:5 ratio to three groups: placebo (n = 6), praliciguat 40 mg once daily for days 1-14 (n = 10), or praliciguat 20 mg twice daily for days 1-7 then 40 mg once daily for days 8-14 (n = 10). Assessments were made in clinic and included treatment-emergent adverse events, pharmacokinetics, metabolic variables, 24 h BP and heart rate, platelet function, reactive hyperaemia index (RHI) and plasma biomarkers. Participants, the sponsor, the investigator and clinic study staff (except designated pharmacy personnel) were blinded to group assignment. RESULTS: Participants treated for 14 days with praliciguat had least-square mean change-from-baseline differences vs placebo (95% CI) of -0.7 (-1.8, 0.4) mmol/l for fasting plasma glucose, -0.7 (-1.1, -0.2) mmol/l for total cholesterol, -0.5 (-1.0, -0.1) mmol/l for LDL-cholesterol, -23 (-56, 9) for HOMA-IR in those not being treated with insulin, and -5 (-10, 1) mmHg and 3 (-1, 6) beats/min for average 24 h mean arterial pressure and heart rate, respectively. Apart from one serious adverse event (SAE; upper gastrointestinal haemorrhage), praliciguat was well tolerated. Praliciguat did not affect platelet function or RHI. Among exploratory biomarkers, plasma levels of asymmetric dimethylarginine decreased in praliciguat vs placebo recipients. CONCLUSIONS/INTERPRETATION: In participants with type 2 diabetes and hypertension on standard therapies, over 14 days praliciguat was well tolerated, except for a single SAE, and showed positive trends in metabolic and BP variables. These results support further clinical investigation of praliciguat. TRIAL REGISTRATION: ClinicalTrials.gov NCT03091920. FUNDING: This trial was funded by Cyclerion Therapeutics.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Hanrahan JP, Seferovic JP, Wakefield JD, et al. An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. Diabetologia. 2019. PMID: 31858186. doi:10.1007/s00125-019-05062-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。